KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Free Cash Flow (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Free Cash Flow data on record, last reported at $348.6 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 29.15% year-over-year to $348.6 million; the TTM value through Dec 2025 reached $3.2 billion, up 504.13%, while the annual FY2025 figure was $3.2 billion, 504.13% up from the prior year.
  • Free Cash Flow reached $348.6 million in Q4 2025 per VRTX's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.3 billion in Q3 2024 and bottomed at -$3.8 billion in Q2 2024.
  • Average Free Cash Flow over 5 years is $603.7 million, with a median of $897.0 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: skyrocketed 535.3% in 2022, then tumbled 455.66% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $933.2 million in 2021, then rose by 11.96% to $1.0 billion in 2022, then plummeted by 83.11% to $176.5 million in 2023, then surged by 178.75% to $492.0 million in 2024, then fell by 29.15% to $348.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $348.6 million in Q4 2025, $1.1 billion in Q3 2025, and $927.4 million in Q2 2025.